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Persistent pulmonary hypertension of the newborn (PPHN) is a cyanogenic plurifactorial disorder characterized by
failed postnatal drop of pulmonary vascular resistance and maintenance of right-to-left shunt across ductus arteriosus
and foramen ovale typical of intrauterine life. The pathogenesis of PPHN is very complex and can result from functional
(vasoconstriction) or structural (arteriolar remodeling, reduced pulmonary vessels density) anomalies of pulmonary
circulation. Etiopathogenetic factors heterogeneity can strongly condition therapeutical results and prognosis of PPHN
that is particularly severe in organic forms that are usually refractory to selective pulmonary vasodilator therapy with
inhaled nitric oxide. This paper reports the more recent acquisitions on molecular physiopathogenetic mechanisms
underlying functional and structural forms of PPHN and illustrates the bases for adoption of new potential treatment
strategies for organic PPHN. These strategies aim to reverse pulmonary vascular remodeling in PPHN with arteriolar
smooth muscle hypertrophy and stimulate pulmonary vascular and alveolar growth in PPHN associated with lung
hypoplasia.In order to restore lung growth in this severe form of PPHN, attention is focused on the results of studies of
mesenchymal stem cells and their therapeutical paracrine effects on bronchopulmonry dysplasia, a chronic neonatal
lung disease characterized by arrested vascular and alveolar growth and development of pulmonary hypertension.
Keywords: Persistent neonatal pulmonary hypertension, Pulmonary vascular remodeling, Pulmonary vessels
underdevelopment, Lung hypoplasia, Pulmonary vasodilative therapy, Stem cells based therapyIntroduction
Persistent pulmonary hypertension of the newborn
(PPHN), first described as “persistence of fetal circula-
tion” by Gersony and Sinclair in 1969 [1], is a cyano-
genic disorder characterized by the lack of postnatal
drop of pulmonary vascular resistance and by the per-
sistence of the typical intrauterine right-to-left shunting
of blood through foramen ovale and ductus arteriosus.
The incidence of PPHN is between 0.43 and 6.6 new-
borns per 1000 live births and is most common in term
and near term newborns [2-4]. Despite the major ad-
vances in treatment of newborns with cardiorespiratory
diseases, PPHN is still one of the main causes of neo-
natal death, mortality being around 10-20% [5]. The* Correspondence: pietrosciacca@hotmail.it
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article, unless otherwise stated.severe outcome of PPHN is probably linked to the broad
spectrum of etiopathogenetic factors some of which can
negatively influence therapeutical results. Recent re-
searches on the development of PPHN have shown the
important role of perinatal fetal environment (e.g. smoke
and drug exposure, stress or pain, maternal obesity and
diabetes, caesarean section etc.) plus the epigenetic
changes that pre and postnatal stimuli can determine in
the expression of genes involved in perinatal pulmonary
circulation regulation [6-8].
The purpose of this article is to review the physiopato-
genetic aspects of PPHN and underline the molecular
mechanisms that can constitute the basis of new poten-
tial therapeutical strategies for severe forms of PPHN
that are resistant to current treatment.d Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Pulmonary arteriole from one-day-old infant. The
medial muscle mass is conspicuous (Verhoeff’s and Van Gieson’s
stains). From Naeye and Letts [20], Pediatrics 1962.
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During intrauterine life, pulmonary vascular resistance is
elevated and systemic resistance low, fetal channels
(ductus arteriosus and foramen ovale) are patent with
right-to-left shunt and both ventricles work in parallel
instead of in series.
Elevated fetal pulmonary vascular resistance is partly
caused by pulmonary collapse and vessels tortuosity but
above all by pulmonary arterioles vasoconstriction. Nor-
mally these arterioles present a muscular medial tunic
up to the preacinar zones then disappearing in intraaci-
nar branches [9]. In physiological conditions the periar-
teriolar muscular layer develops mainly during the last
months of gestation and thus is not well represented in
preterms [10]. A thicker muscle layer results in a nar-
rower lumen and reduced arterioles compliance, and this
may play a role in increased vascular pulmonary resist-
ance, regardless of vasoconstriction [10]. Relative hypoxia
in the blood perfusing the fetal lung plays an important
role in pulmonary arteriolar vasoconstriction. Pulmonary
arteriolar muscle fibers are very sensitive to oxygen ten-
sion and pH variations and they contract in conditions of
hypoxia and acidosis and relax when Pa02 and pH in-
crease [11]. Pulmonary arteriolar tone can also be influ-
enced by several humoral factors present in the perinatal
circulation. Some of these (thromboxane, endothelin etc.)
possess a vasoconstricting action, whereas others (prosta-
cyclin, nitric oxide, etc.) determine vasodilatation [12,13].
At birth systemic resistance rises rapidly. On the con-
trary, when breathing starts pulmonary resistance falls after
lung and pulmonary vascular bed expansion and, in par-
ticular, following arteriolar dilatation caused by the rapid
increase of arterial oxygen tension. Oxygen can act directly
on myocytes, but its action is mainly mediated by humoral
factors (specially prostacyclin and nitric oxide) secreted by
the pulmonary arteriolar endothelium, a tissue that per-
forms a key function in perinatal pulmonary circulation
regulation [10,12,14,15]. Secretion of these vasodilating
agents can also be induced by mechanical stimuli such as
ventilation and shear stress caused by vascular bed disten-
sion and abrupt increment of pulmonary blood flow [5].
Nitric oxide (NO) is produced by endothelial NO syn-
thase (eNOS) using L-arginine as substrate and producing
L-citrulline as a by-product. L-citrulline in turn can be
reconverted in L-arginine through a recycling pathway
that is the principal source of L-arginine available to eNOS
[16]. eNOS is activated by the sudden increase in postnatal
oxygen tension [3]. NO determines pulmonary vasodilata-
tion via soluble guanylate cyclase stimulation and the en-
suing increase of cyclic guanylate monophosphate (cGMP)
concentrations in vessel smooth muscle cells [17]. cGMP
endomyocytic levels are regulated by phosphodiesterase
5 (PDE5), a kinase enzyme abundantly expressed in
pulmonary tissue during fetal life and able to hydrolyzecGMP [18]. Pulmonary arterioles vasodilatation at birth
is inversely correlated to the thickness that their mus-
cular tunic reaches at the end of gestation. Histological
observations [19,20,12] revealed that the muscular
tunic is progressively reabsorbed during the postnatal
period (Figures 1, 2, 3 and 4). This process is sustained
by apoptotic events involving pulmonary vessel myo-
cytes and is generally completed within the first two
weeks of life. However, sometimes it may take some
days longer and thus impact negatively on postnatal
circulation adjustments as the muscular tunic thickness
narrows the lumen and makes the pulmonary arterioles
more reactive to vasoconstricting stimuli [21,22].
Physiopathology of PPHN
The fundamental physiopatological feature of this syn-
drome is the failure of the postnatal drop in pulmonary
vascular resistance, and the presence of elevated pressure
values in the pulmonary artery and right sections of the
heart [7]. This maintains the typical fetal intrauterine
right-to-left shunt in the ductus and foramen ovale result-
ing in cyanosis and severe hypoxemia refractory to oxygen
therapy. Hypoxemia and the ensuing metabolic acidosis
determine in turn arteriolar vasoconstriction, leading to a
further increase in pulmonary vascular resistance, and if
this vicious circle is not rapidly eradicated by adequate
treatment the negative clinical and hemodynamic situation
tends to worsen producing a progressive cardiac dysfunc-
tion with fatal outcome (Figure 5).
Pathogenesis of PPHN
Pathogenetically there are two forms of PPHN: one
functional where elevated vascular pulmonary resistance
is only due to pulmonary arteriolar vasoconstriction, and
the other organic where vasoconstriction is of secondary
importance and increased resistance is mainly caused by
Figure 2 Pulmonary arteriole from a polymalformed non
hypoxemic term infant who died at 6 days of life. Medial muscle
mass is still evident (H.E. stains). From Distefano G et al. [12], Med
Surg Ped 1992. (Personal observation).
Figure 4 Pulmonary arterioles from a 22-day-old infant who
died from bilateral kidney malformation. Marked thinning of
medial muscle mass is evident (PAS-Gieson stains). From Distefano G
et al. [12], Med Surg Ped 1992. (Personal observation).
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tion. These changes are generally represented by pulmon-
ary arterioles lumen narrowing caused by muscular tunic
hypertrophy and extension of smooth muscle to the
intraacinar branches (normally without muscle fibers), or
by poor pulmonary vessels development that reduces the
size of the pulmonary vascular bed and thus increases
blood flow resistance. Organic forms of PPHN include
rare, and almost always fatal, cases of alveolar capillary
dysplasia caused by diffuse misalignment of the arteriolar
capillary venous axis that compromises respiratory ex-
change [23]. Both functional and organic forms of PPHN
can be primary or secondary and have diverse causes [24].Functional PPHN
Postnatal persistence of fetal pulmonary vasocon-
striction Functional PPHN can be idiopathic or, moreFigure 3 Pulmonary arteriole from a 4-week-old non hypoxemic
infant. The relative medial muscle mass has decreased since birth
(Verhoeff’s and Van Gieson’s stains). From Naeye and Letts [20],
Pediatrics 1992.frequently, secondary to various pathologies. In the idio-
pathic form, postnatal persistence of fetal pulmonary vaso-
constriction is considered the expression of constitutional
and/or genetic factors enhancing sensibility of pulmonary
arterioles to vasoconstrictive stimuli or impairing mecha-
nisms of NO release and action [25-27]. Reently some
PPHN patients have shown variants in the genes of
corticotrophin-releasing hormone receptor 1 and of its
binding protein (CRHR1 and CRHBP genes). This deter-
mines reduced expression of “Peroxisome proliferator-
activated receptor-gamma (PPAR-γ)”, a transcription factor
that plays an important role in myocytes proliferation and
pulmonary arteriolar tone regulation [28-30]. In the sec-
ondary form, the majority of cases are due to perinatal as-
phyxia, present in 80-90% of the subjects, and septic
processes caused by group B streptococcus, e.g. pneumonia
[1,2]. Asphyxia and sepsis can determine pulmonary arteri-
olar vasoconstriction, either directly through hypoxia and
acidosis or indirectly via release of vasoactive substances,
such as leukotrienes, endothelin, free radicals, thromb-
oxane, etc. [31-33] (Figure 6). Thromboxane seems to play
a major role in sepsis. In experimentally induced strepto-
coccal infections it was observed that cycloxygenase inhibi-
tors, such as indomethacin, can prevent pulmonary
hypertension [34]. Recent studies have revealed that vaso-
constriction can also be determined by some phospholipids
(in particular, phosphatidyl-glycerol and cardiolipin) present
in the bacterial wall of streptococcus B [35]. Studies on
perinatal asphyxia have focused on leukotrienes [36] and,
especially, on endothelin whose plasma concentrations
were markedly higher than observed in normal controls
[37]. Reactive oxygen species (ROS), derived from metabol-
ism of hypoxanthine, play a concomitant role in asphyxia
[31]. In effect, oxidative stress seems able to enhance signals
promoting endothelin production and reducing nitric oxide
synthase (NOS) expression [38]. Moreover, recent studies
reported that ROS pulmonary vasoconstrictive action can
Figure 5 Physiopathology of PPHN. Vicious circle leading to progressive cardiac dysfunction.
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phyxia, hypoxemia not only contracts pulmonary arterioles
but, if prolonged, is also able to hinder muscular tunic
reabsorption promoting its hypertrophy as observed in
histopathological studies [20,12], (Figures 7 and 8). Similar
morphological observations have been reported also in ani-
mals with induced postnatal hypoxemia [40]. Among the
pulmonary parenchymal diseases associated with perinatal
asphyxia - such as meconium aspiration syndrome (MAS),
respiratory distress syndrome (RDS) and pneumonia
(PM) - the most frequent observed in newborns with
PPHN is MAS where endothelin (principally) and uroten-
sin play an important role as powerful pulmonary vasocon-
strictive agents [41,42].Organic PPHN
Hypertrophy of pulmonary arteriolar muscular tunic
The first descriptions of such structural anomaly were
reported many years ago in histopathological studies onFigure 6 Pathogenesis of functional PPHN in perinatal asphyxia and nnewborns who died from PPHN and were not affected
by neonatal asphyxia or other intercurrent pathologies
[43,21,22]. Increased muscular tunic thickness reduces
lumen caliber, leading to marked narrowing of the pul-
monary arterioles and consequent obstructive type blood
flow resistance. As etiology is uncertain, these forms
of organic PPHN have been labeled as idiopathic [43].
Some authors believe that genetics may influence these
forms of PPHN causing a primitive increased thickness
of the muscular tunic of pulmonary arterioles [44].
Other studies have revealed that muscular tunic hyper-
trophy can be secondary to pathological events occur-
ring during gestation and be observed, for example, in
newborns subjected to accentuated chronic intrauterine
hypoxia or increase of fetal pulmonary arterial pressure
(Figure 9). The first event occurs during intrauterine
conditions accompanied by chronic placental insuffi-
ciency and can explain the findings of the afore-
mentioned vascular changes in small for date newborns
[12] (Figure 10). The second event can occur in cases ofeonatal sepsis.
Figure 7 Pulmonary arteriole from a 6-week-old hypoxemic
infant. The relative medial muscle mass present at birth has been
retained (Verhoeff’s and Van Gieson’s stains). From Naeye and
Letts [20], Pediatrics 1962.
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borns of pregnant women treated with prostaglandin
synthetase inhibitors (indomethacin, salicylates, lithium
etc.) [45] (Figure 9). The important role of chronic hyp-
oxemia and of fetal pulmonary arterial pressure incre-
ment in determining smooth muscle hypertrophy in
pulmonary arterioles has been demonstrated in experi-
mental models of PPHN reproduced in lamb fetuses
[46,47]. Molecular studies revealed that these two factors
act on the pulmonary endothelium and can inhibit the
release of NO and stimulate that of endothelin and of
smooth muscle mitogens inducing pulmonary vessels
myocytes hypertrophy [48,49,4,6]. PDE5, an enzyme that
degrades cGMP and jeopardizes the pulmonary vasodi-
lating effect of NO, was markedly increased in lamb
fetuses with chronic pulmonary hypertension induced by
ductus ligation. Recent researchs have shown that the
afore-mentioned structural changes in fetal pulmonaryFigure 8 Pulmonary arteriole from a 11-day-old infant who
died from severe perinatal asphyxia. Marked thickening of medial
muscle mass is evident (PAS-Gieson stains). From Distefano G et al.
[12] Med Surg Ped 1992. (Personal observation).arterioles can also occur when there is chronic use of
selective serotonin reuptake inhibitors (antidepressant
drugs) during pregnancy [50,51]. In effect, serotonin is
a powerful pulmonary vasoconstrictor that stimulates
smooth muscle cell growth and proliferation [50].
Underdevelopment of pulmonary vascular bed In this
form of PPHN the failed postnatal drop of pulmonary
resistance is due to diminished number of pulmonary
vessels that, decreasing the cross-sectional area of pul-
monary vascular bed, causes a restrictive type enhance-
ment of resistance to pulmonary blood flow. This severe
hemodynamic situation is typical of pulmonary hypopla-
sia, a condition often associated with congenital dia-
phragmatic hernia (CDH) [9]. Indeed, it has been clearly
documented that normal pulmonary vessel development
is crucial for pulmonary alveoli growth and is regulated
by various biochemical factors, in particular vascular
endothelial growth factor (VEGF), a potent vascular cell
mitogen and modulator of angiogenesis [52,53]. Studies
on lamb fetuses demonstrated that inhibition of VEGF
receptors impairs vascular growth and provokes pul-
monary hypertension [54]. Impairment of alveolarization
and vascular growth associated with reduced VEGF
expression has been reported also in animals with
chronic intrauterine pulmonary hypertension induced by
ductus ligation [55]. The hypoplastic CDH lung, in
addition to reduced vessels density, presents increased
vascular reactivity to vasoconstricting stimuli associated
with reduced nitric oxide synthase (NOS) expression
and elevated endothelin production [23,56,57,6].
Current medical treatment of PPHN
PPHN treatment is influenced by the multiplicity of etio-
pathogenic factors, the severity of pulmonary hyperten-
sion and by heart and lung function alterations. It
includes a general therapy aimed at stabilizing the new-
borns’ clinical conditions, and a more important specific
treatment with pulmonary vasodilators aimed at elimin-
ating the right-to-left shunt causing severe hypoxemia
[2,3,7,12,58]. If such treatment fails, extracorporeal
membrane oxygenation (ECMO) is required [59]. General
therapy,that has been well codified for several years [12,7],
and ECMO will not be addressed in this paper.
Pulmonary vasodilator therapy
Pulmonary vasodilators are essential in the treatment of
PPHN to achieve the reversal of the right-to-left shunt
causing hypoxemia and cyanosis.
The advent of nitric oxide (NO) therapy represented a
turning-point in the treatment of PPHN. Many clinical
and experimental studies have shown that inhaled nitric
oxide (iNO), unlike other vasodilators (tolazoline, mag-
nesium sulfate etc.) acting also on the systemic circle
Figure 9 Pathogenesis of pulmonary vascular remodeling in organic PPHN.
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monary arterial circulation and eliminates pulmonary
hypertension related hypoxemia [61-63]. iNO spreads
through the alveolar epithelium to smooth muscle of the
underlying vessels and dilates the pulmonary arterioles,
while the part that reaches the vessel lumen, through
which it could enter the peripheral circulation and cause
systemic hypotension, is rapidly inactivated by combin-
ation with hemoglobin and formation of methaemoglobin
[63]. In PPHN, iNO rapidly improves the oxygenation sta-
tus and reduces the need for ECMO [64,65,63,2]. In a
recent randomized comparative study Gonzalez et al. [66],
showed that the best results with iNO were obtained when
therapy was administered early on. Nevertheless clinical
experience has demonstrated that iNO therapy is effective
only in 50–60% of PPHN patients [67,2]. In all likelihood,
this depends on the pathogenesis with optimal response toFigure 10 Pulmonary arteriole from a small for date newborn
who died at 2 days of life from esophageal atresia. Marked
thickening of medial muscle mass is evident (H.E. stains). From
Distefano G et al. [12], Med Surg Ped 1992. (Personal observation).treatment in functional PPHN, that is induced only by pul-
monary arteriolar vasoconstriction, and partial or absent
response in organic PPHN where structural alterations of
pulmonary arterioles sustain stable pulmonary vascular
resistance.
PPHN refractory to INO can also be linked to disrup-
tions in the complex down stream signaling pathways
activated by the same NO and negatively interfering with
its action on vascular myocytes. These changes are
sometimes induced by epigenetic alterations and include
various anomalies, such as reduced response of guany-
late cyclase to NO, reduced expression or activity of
guanylate cyclase, increased clearance of cGMP by
phosphodiesterase [68]. In cases of resistant PPHN to
INO therapy, an alternative treatment could be the use
of PDE inhibitors that preventing cGMP degradation
and raising its intramyocytic concentration, promote
pulmonary arterioles vasodilation [63,2]. One of these
substances, the powerful PDE5 inhibitor sildenafil, has
attracted most attention. PDE5 is the most expressed
isoform in the lung during the perinatal period and its
activity is increased in PPHN animal models [7]. Oral or
intravenous administration of sildenafil is able to lower
pulmonary vascular resistance with poor impact on sys-
temic resistance in experimental and clinical studies
[69-71]. Some studies revealed its efficacy also in cases
of PPHN associated with congenital diaphragmatic her-
nia where it can improve pulmonary vascular function
and promote pulmonary growth [72]. Furthermore it has
been reported that this drug enhances vasodilative re-
sponse to endogenous nitric oxide and thus prevents
pulmonary hypertension rebound after the suspension of
nitric oxide therapy [70]. Adenosine, an eNOS agonist,
could increase the formation of N0 and because of its
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effects. However, the experience using this substance in
PPHN is still very limited [3]. Additional pulmonary
vasodilatory effect in cases of PPHN not responding well
to INO therapy has been reported using inhaled prosta-
cyclin (PGI2) and intravenous infusion of milrinone.
These substances trigger off complementary effects on
pulmonary vascular myocytes to those obtained by NO
as they raise cAMP intracellular concentrations. PGI2
directly stimulates adenil cyclase, while milrinone acts
indirectly by inhibiting PDE3, a cAMP hydrolyzing
enzyme. However, to date controlled studies confirming
their efficacy are lacking [63,3]. A recent randomized,
double-blind, placebo-controlled, prospective study in 47
newborns infants with PPHN showed that Bosentan, an
endothelin-1 antagonist, is an efficacious pulmonary
vasodilator [73].
Despite progress in PPHN therapy, this syndrome has
still a severe prognosis. Clearly, the major problems involve
newborns presenting structural changes in pulmonary
circulation, such as muscle hypertrophy and pulmonary
vascular bed hypoplasia that reduce the efficacy of vasodila-
tor therapy also when it acts selectively on pulmonary ves-
sels. Advances in molecular pathogenetic studies seem to
offer new potential therapeutic solutions for these severe
cases of PPHN.
New potential therapeutical strategies
Increasing knowledge of complex molecular mechanisms
involved in the muscularization process of pulmonary
arterioles and the development of pulmonary vascular
bed, forms the basis for new therapeutic strategies aimed
at promoting periarteriolar muscle involution in PPHN
associated with pulmonary vascular remodeling, and atFigure 11 Role of Endothelin in the pathogenesis of pulmonary vascu
negative effect of superoxide can be counteracted by Nitric oxide-donors a
Nitric oxide bioavailability (see text).stimulating angiogenic processes in PPHN associated
with underdevelopment of pulmonary vasculature.
A major role in pulmonary vascular remodeling seems
to be played by endothelin-1 (ET-1) whose concentra-
tions are increased in newborns with PPHN. ET-1 not
only has a well known vasoconstrictive action, but also
stimulates proliferation of pulmonary arterial smooth
muscle cells (PASMCs), as observed by Wedgwood et al.
[74] in in vitro studies on PASMCs isolated from lamb
fetuses. These effects are linked to ETa receptors activa-
tion in the PASMCs; in fact blockade of these receptors
attenuated fetal pulmonary hypertension and inhibited
pulmonary periarteriolar musculature hypertrophy in
ovine models where PPHN was induced by ductal ligation
[74]. Furthermore, these authors observed that the mito-
genic effect on PASMCs linked to ETa receptors stimula-
tion was mediated by NADPH oxidase through increased
production of superoxide, that in turn stimulate activation
of mitogen-activated protein(MAP) kinases, and can be
prevented by antioxidant treatment and by NADPH oxi-
dase inhibition [75] (Figure 11). In further studies on lamb
fetuses the same authors [76] reported that PASMACs
proliferation induced by ET-1 via the superoxide can be
inhibited by both endogenous and exogenous NO. Using
the NO donor spermine NONOate they observed that ni-
tric oxide released by this substance, reacting with super-
oxide to form peroxynitrite, lowers superoxide levels
preventing its stimulating effect on PASMCs proliferation
and viability and can also determine apoptosis of the same
PASMCs through the activation of pro-apoptotic caspases
enzymes [76]. Increased superoxide production in pul-
monary arteries and elevated ET-1 concentrations associ-
ated with reduced NO production have been found in
lambs with chronic ductal ligation-induced PPHN [77,78].lar remodeling in organic PPHN. In animal models of PPHN the
nd L-citrulline enhancing, respectively, exogenous and endogenous
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tration of NO, also through use of NO donors, combined
with antioxidant therapy could be a useful therapeutic tool
to reverse smooth muscle hypertrophy in severe forms of
PPHN associated with pulmonary vascular remodeling. In
order to increase NO availability, some authors have taken
into consideration therapeutical use of L-citrulline. This
substance in fact, is capable of enhancing endogenous ni-
tric oxide production via its action that improves pulmon-
ary eNOS function [16]. Recently a study in newborn
piglets exposed to 10 days of chronic hypoxia showed that
pulmonary hypertension development can be prevented
by supplementation of L-citrulline [79]. In children under-
going cardiopulmonary bypass for cardiosurgery it has
been observed that L-citrulline supplementation was able
to prevent postoperative pulmonary hypertension [80]. If
these results are confirmed by a larger series of studies,
the use of L-citrullin could be a useful remedy for prevent-
ing the development of pulmonary hypertension and vas-
cular remodeling in neonates affected by pathologies
associated with prolonged hypoxia.
Regarding PPHN with reduced pulmonary vascular
bed it is known that the syndrome is typical of the
pathological conditions associated with pulmonary hypo-
plasia, in particular congenital diaphragmatic hernia
(CDH) [9]. Reduced pulmonary vessel density has also
been observed in clinical and experimental forms of
PPHN secondary to chronic intrauterine fetal pulmonary
hypertension [55,7].
Following embryonic vasculogenesis where primordial
vascular structures are formed, pulmonary circulatory
network development is induced by angiogenesis a bio-
logical process regulated by a series of transcription and
growth factors, in particular VEGF that is paramount in
pulmonary vessel growth [13]. In the human fetal lung,
VEGF is expressed in epithelial cells and myocytes while
its receptors are located in endothelial cells closely
apposed to the developing epithelium [81]. VEGF’s an-
giogenic effect on pulmonary endothelium is mediated
by NO produced by the activation of endothelial nitric
oxide synthase (eNOS) [82]. Reduced VEGF expression
with impaired nitric oxide signals has been reported in
experimental PPHN models associated with chronic fetal
pulmonary hypertension after in utero ductal ligation,
and with nitrofen-induced diaphragmatic hernia. Both
these conditions present vascular remodeling and re-
duced pulmonary vessel density [54,83]. NO adminis-
tered to rats with nitrofen-induced CDH to stimulate
angiogenesis enhanced lung growth [13]. The results of
this research suggest that cases of PPHN associated with
reduced pulmonary vessels development could benefit
from prolonged treatment with iNO or with NO donors.
Benefits would be two-fold as such therapy could deter-
mine the regression of periarteriolar muscular hypertrophy,and also stimulate pulmonary angiogenesis. On the other
hand, reduced eNOS expression with low blood levels of
NO has been reported in human newborns with diaphrag-
matic hernia [56] and in experimental animal models with
PPHN associated with chronic hypoxia and pulmonary
hypertension [84,85]. Recently Teng et al. performed
in vitro studies on pulmonary artery endothelial cells
(PAEC) isolated from lambs with intrauterine ductal
ligation-induced PPHN and showed that angiogenesis can
be strongly stimulated by sepiapterin, a substance capable
of increasing intracellular levels of tetrahydrobiopterin
(BH4) that are low in these cells. BH4 is a cofactor of crit-
ical importance to maintain active eNOS catalytic function
for NO production, and in PAEC of these PPHN lambs
can be inactivated by its oxidation in dihydrobiopterin
(BH2), due to increased peroxynitrite formation in these
cells [86]. Moreover, in their previous study using the same
PPHN lamb model, Teng et al. [87] showed that impaired
angiogenesis in PAEC improved after addition of antioxi-
dants on tissue culture media. The results of such re-
searches suggest that the use of sepiapterin to increase
PAEC BH4 intracellular levels might be a potentially useful
therapy for improving eNOS function and restoring angio-
genesis in PPHN cases with reduced density of pulmonary
vessels. Furthermore, the effectiveness of this treatment
could be potentiated by combining sepiapterin supplemen-
tation and antioxidant therapy.
Future perspectives in PPHN with lung hypoplasia
In this field, very interesting therapeutical perspectives
are emerging from experimental studies on bronchopul-
monary dysplasia (BPD), a chronic neonatal lung disease
characterized by arrested vascular and alveolar growth
and development of pulmonary hypertension. They indi-
cate the potential use of mesenchymal stem cells (MSCs)
or endothelial progenitors cells (EPCs) for restoring vas-
cular and alveolar growth [88,89]. MSCs are multipotent
cells capable of self-renewal and differentiating into vari-
ous cell types, including parenchymal and vascular pul-
monary cells, and can be obtained from bone marrow
(BM), umbilical cord blood (UCB) and adipose tissue
[89]. EPCs are BM or UCB-derived vascular precursor
cells which can be circulating and also resident within
vessels wall. Recently several studies In various animal
models of BPD have demonstrated that intravenous or
intratracheal delivery of bone marrow-derived MSCs
(BMSCs) was capable of regenerating lung vascular and
alveolar growth and reversing associated pulmonary
hypertension [90]. The same effects in BPD models have
been obtained with human UCB-derived EPCs [91].
However, a very important acquisition emerging from
stem cells studies is that, rather than cells replacement,
the beneficial therapeutic effect of BM and UCB-derived
MSCs or EPCs can be mediated through a paracrine
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intrapulmonary engraftment rates of these transplanted
cells and supported by in vitro and in vivo studies show-
ing that cell-free conditioned media, derived from cul-
tures of these cells, prevent and/or restore arrested
alveolar and vascular growth in neonatal rodents models
of lung injury induced by chronic hyperoxia [92]. MSCs-
derived conditioned media are rich in soluble factors
such as VEGF, stanniocalcin-1 (a potent antioxidant) and
specially exosomes, microvesicles containing microRNAs
molecules and other bioactive molecules involved, re-
spectively, in gene expression regulation, intercellular
communication signals and the control of inflammatory
response. These factors can protect the lung from injuries
inducing alveolar and vascular damage and stimulate prolif-
eration and differentiation of resident epithelial and endo-
thelial progenitors cells and restore pulmonary growth
[92,93]. Recently, the therapeutical importance of exosomes
has been demonstrated by Lee et al. [94] in the rodent
model of chronic hypoxia-induced pulmonary hyperten-
sion. In this model the intravenous delivery of both animal
or human MSC-derived exosomes inhibited vascular
remodeling and development of pulmonary hypertension;
on the contrary, no therapeutical effect was obtained by re-
moving exosomes from MSCs-conditioned media.
Conclusions
PPHN is a plurifactorial syndrome with a complex
pathogenesis sustained by functional (vasoconstriction)
or structural (periarteriolar muscular hypertrophy, re-
duced pulmonary vessels density) pulmonary circulation
anomalies. Despite considerable therapeutical progress
achieved using inhaled nitric oxide (INO), a selective
pulmonary vasodilator, PPHN still remains a major cause
of mortality in all neonatal centers. Prognosis is particu-
larly severe in organic forms, that are refractory to INO
and other alternative pulmonary vasodilators such as sil-
denafil and prostacyclin. Recent advances, in the under-
standing of molecular physiopathogenetic mechanisms,
have paved the way for new potential therapeutical strat-
egies for these organic forms that, as observed in animal
models, could benefit from prolonged use of nitric oxide
donors (NO-donors) and of L-citrulline and sepiapterin.
These substances are capable of increasing, respectively,
the exogenous and endogenous availability of NO. In
PPHN with pulmonary vascular remodeling, increased
circulatory levels of NO can reverse periarteriolar mus-
cular hypertrophy counteracting the stimulating effect of
endothelin-1 (whose concentrations are elevated in these
cases) on pulmonary myocites proliferation and growth.
While in PPHN with reduced density of pulmonary
vessels, high NO levels can stimulate vascular growth
mediating angiogenic effect of VEGF on pulmonary
endothelial cells.Nevertheless, regarding more severe PPHN associated
with lung hypoplasia (as in congenital diaphragmatic
hernia), very fascinating future therapeutical perspectives
are emerging from experimental studies on bronchopul-
monary dysplasia (BPD). Such indicate the possible use
of human umbilical cord blood-derived mesenchymal
stem cells (UCB-derived MSCs) and/or of bioactive fac-
tors obtained by their cultures to restore vascular and
alveolar growth and reverse pulmonary hypertension.
Recently, it has been shown that some of these factors
(exosomes) are, also, effective in inhibiting vascular
remodeling and pulmonary hypertension development in
rodents models of hypoxia-induced PPHN. If the benefi-
cial results achieved in experimental models are con-
firmed by further controlled studies and reproduced in
human newborns, it is reasonable to postulate that, in
near future, the use of bioactive substances obtained by
cultures of human UCB-derived MSCs (easily accessible
at birth) could revolutionize the prognosis of severe
organic PPHN.
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